<DOC>
	<DOCNO>NCT03037580</DOCNO>
	<brief_summary>This multicenter , randomize ( 1:1 ; oral treprostinil placebo ) , double-blind , placebo-controlled study subject World Health Organization ( WHO ) Group 2 pulmonary hypertension ( PH ) associate heart failure preserve ejection fraction ( HFpEF ) . Once randomize , subject take initial dose study drug study site day randomization . Subjects return study site visit schedule Weeks 6 , 12 , 18 , 24 . The treatment phase study last approximately 24 week .</brief_summary>
	<brief_title>Oral Treprostinil Subjects With Pulmonary Hypertension ( PH ) Associated With Heart Failure With Preserved Ejection Fraction ( HFpEF )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . The subject undergone right heart catheterization ( RHC ) within 90 day randomization . 2 . The subject diagnosis heart failure leave ventricular ejection fraction ( LVEF ) ≥50 % . 3 . The subject 's baseline 6MWD must least 200 meter . 4 . The subject pulmonary function test conduct within 6 month Screening Screening phase . 5 . Subjects chronic medication heart failure must stable dose ≥30 day prior randomization . 1 . The subject pregnant lactating . 2 . The subject diagnosis pulmonary arterial hypertension ( PAH ) PH WHO Group 2 PH . 3 . The subject show intolerance significant lack efficacy prostacyclin prostacyclin analogue result discontinuation therapy inability effectively titrate therapy . 4 . The subject receive approved PAH therapy within 60 day randomization . 5 . The subject hospitalize visited emergency department cardiopulmonary indication within 30 day randomization . 6 . The subject myocardial infarction within 90 day randomization . 7 . The subject cardiac resynchronization therapy within 3 month randomization anticipate resynchronization therapy study treatment period . 8 . The subject liver function test great 3 time upper limit normal Screening , clinically significant liver disease/dysfunction , know ChildPugh Class C hepatic disease , noncirrhotic portal hypertension . 9 . The subject uncontrolled systemic hypertension , systolic blood pressure &lt; 100 mmHg , rest heart rate &gt; 100 beat per minute . 10 . The subject know genetic hypertrophic cardiomyopathy , sarcoidosis , cardiac amyloidosis . 11 . The subject known history LVEF le 40 % echocardiogram ( ECHO ) . 12 . The subject follow valvular disease : mild , moderate , severe aortic and/or mitral stenosis , severe mitral and/or aortic regurgitation ( &gt; Grade 3 ) hemodynamically significant valvular disease 13 . The subject Body Mass Index &gt; 40 kg/m^2 . 14 . The subject musculoskeletal disorder , condition limit ambulation . 15 . The subject endstage renal disease requiring/receiving dialysis . 16 . The subject participate investigational drug device study within 30 day prior sign consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>6-Minute Walk Test</keyword>
	<keyword>HFpEF</keyword>
	<keyword>Oral Treprostinil</keyword>
</DOC>